DK1553953T3 - Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom - Google Patents
Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucomInfo
- Publication number
- DK1553953T3 DK1553953T3 DK03758746.6T DK03758746T DK1553953T3 DK 1553953 T3 DK1553953 T3 DK 1553953T3 DK 03758746 T DK03758746 T DK 03758746T DK 1553953 T3 DK1553953 T3 DK 1553953T3
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- glaucoma
- treatment
- latanoprost
- ocular hypertension
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 206010030043 Ocular hypertension Diseases 0.000 title abstract 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 title abstract 2
- 229960001160 latanoprost Drugs 0.000 title abstract 2
- 208000001344 Macular Edema Diseases 0.000 abstract 2
- 206010025415 Macular oedema Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 201000010230 macular retinal edema Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960000686 benzalkonium chloride Drugs 0.000 abstract 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Solid Thermionic Cathode (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42077602P | 2002-10-24 | 2002-10-24 | |
| US42104402P | 2002-10-25 | 2002-10-25 | |
| US10/429,677 US7074827B2 (en) | 2002-10-24 | 2003-05-06 | Method for treating ocular hypertension and glaucoma |
| PCT/JP2003/013452 WO2004037267A1 (en) | 2002-10-24 | 2003-10-22 | Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1553953T3 true DK1553953T3 (da) | 2010-10-25 |
Family
ID=32110845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03758746.6T DK1553953T3 (da) | 2002-10-24 | 2003-10-22 | Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7074827B2 (da) |
| EP (2) | EP1553953B1 (da) |
| JP (2) | JP2006503913A (da) |
| AT (1) | ATE480240T1 (da) |
| AU (1) | AU2003274734A1 (da) |
| CA (1) | CA2502437C (da) |
| DE (1) | DE60334134D1 (da) |
| DK (1) | DK1553953T3 (da) |
| WO (1) | WO2004037267A1 (da) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004283091A1 (en) * | 2003-10-03 | 2005-05-06 | Allergan, Inc. | Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia |
| DE602004017477D1 (de) * | 2004-11-09 | 2008-12-11 | Novagali Pharma Sa | Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential |
| GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
| DE102005035986B4 (de) * | 2005-07-28 | 2009-10-15 | Bausch & Lomb Incorporated | Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat |
| PT1937212E (pt) * | 2005-10-10 | 2010-11-30 | Novagali Pharma Sa | Emulsões oftálmicas contendo prostaglandinas |
| US7666912B2 (en) * | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
| TWI394564B (zh) * | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
| KR101421519B1 (ko) * | 2006-09-28 | 2014-07-30 | 알콘 리서치, 리미티드 | 자기 보존 수성 약제학적 조성물 |
| FR2912207B1 (fr) * | 2007-02-01 | 2012-10-26 | Air Liquide | Procede et appareil de production de monoxyde de carbone par distillation cryogenique |
| WO2008096804A1 (ja) * | 2007-02-07 | 2008-08-14 | Teika Pharmaceutical Co., Ltd. | ラタノプロスト含有点眼剤 |
| JP2008247828A (ja) * | 2007-03-30 | 2008-10-16 | Wakamoto Pharmaceut Co Ltd | ラタノプロストを含有する水性医薬組成物。 |
| FR2918891B1 (fr) * | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
| JP2009040727A (ja) * | 2007-08-09 | 2009-02-26 | Towa Yakuhin Kk | ラタノプロストを有効成分とする安定な点眼液剤 |
| EP2193795B1 (en) * | 2007-08-29 | 2014-10-01 | Wakamoto Pharmaceutical Co., Ltd. | Latanoprost-containing aqueous pharmaceutical composition |
| MX2007011165A (es) * | 2007-09-12 | 2009-03-11 | Arturo Jimenez Bayardo | Composición farmacéutica estable de timolol, dorzolamida y brimonidina. |
| TWI544927B (zh) * | 2008-03-17 | 2016-08-11 | 愛爾康研究有限公司 | 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物 |
| ES2638771T3 (es) * | 2008-03-17 | 2017-10-24 | Novartis Ag | Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol |
| EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
| EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| JP2010275259A (ja) * | 2009-05-29 | 2010-12-09 | Toa Yakuhin Kk | 均一、かつ安定なラタノプロスト点眼液剤組成物 |
| TWI489997B (zh) * | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | 含有硼酸－多元醇錯合物之水性藥學組成物 |
| EP2269575A1 (en) | 2009-06-30 | 2011-01-05 | Santen Pharmaceutical Co., Ltd | Method for improving bioavailability of latanoprost |
| EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| WO2011113855A2 (en) | 2010-03-17 | 2011-09-22 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| FR2961694B1 (fr) * | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| US9078854B2 (en) | 2010-07-29 | 2015-07-14 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| CA2806973A1 (en) * | 2010-07-29 | 2012-02-02 | Allergan, Inc. | Preservative free bimatoprost solutions |
| EP2452669A1 (en) | 2010-10-29 | 2012-05-16 | Omnivision GmbH | Ophthalmic composition |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| ES2687494T3 (es) | 2011-01-19 | 2018-10-25 | Topokine Therapeutics, Inc. | Métodos y composiciones para reducir la grasa corporal |
| US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
| JP6329130B2 (ja) * | 2012-04-10 | 2018-05-30 | アイノビア，インコーポレイティド | 噴霧エジェクタ機構、電荷分離及び制御可能な液滴電荷を提供する装置、並びに低投与量の点眼 |
| EP2838669B1 (en) | 2012-04-20 | 2018-01-03 | Eyenovia, Inc. | Spray ejector device and methods of use |
| WO2013173321A1 (en) | 2012-05-14 | 2013-11-21 | Corinthian Ophthalmic, Inc. | Laminar flow droplet generator device and methods of use |
| EA201492094A1 (ru) | 2012-05-15 | 2015-04-30 | Айновиа, Инк. | Эжекторные устройства, способы, возбудители и схемы для них |
| CN113679697A (zh) | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| DK3181119T3 (da) | 2012-09-12 | 2019-09-16 | Novaliq Gmbh | Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca |
| WO2014081941A1 (en) | 2012-11-21 | 2014-05-30 | Topokine Therapeutics, Inc. | Methods and compositions for locally increasing body fat |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| NO2753788T3 (da) | 2013-05-10 | 2018-06-16 | ||
| WO2014186504A1 (en) | 2013-05-15 | 2014-11-20 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
| WO2015029923A1 (ja) * | 2013-08-26 | 2015-03-05 | ロート製薬株式会社 | 眼科用製剤 |
| GR1008483B (el) * | 2013-12-23 | 2015-05-12 | Rafarm Α.Ε.Β.Ε., | Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης |
| US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
| JP6604328B2 (ja) | 2014-08-05 | 2019-11-13 | ソニー株式会社 | 直流電力送電装置、直流電力受電装置及び直流電力送電システム |
| MX2018003781A (es) | 2015-09-30 | 2018-09-12 | Novaliq Gmbh | Compuestos semifluorados para administracion oftalmica. |
| CN108348777B (zh) | 2015-09-30 | 2020-04-28 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| GR1009040B (el) * | 2016-04-19 | 2017-05-19 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου |
| USRE50060E1 (en) | 2016-06-23 | 2024-07-30 | Novaliq Gmbh | Topical administration method |
| ES2969758T3 (es) | 2016-09-22 | 2024-05-22 | Novaliq Gmbh | Composiciones farmacéuticas para usar en la terapia de la blefaritis |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| PT3399962T (pt) | 2016-12-23 | 2020-09-03 | Novaliq Gmbh | Composição oftálmica para o tratamento da doença do olho seco |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| KR20200059272A (ko) | 2017-09-27 | 2020-05-28 | 노바리크 게엠베하 | 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| EP3758676A1 (en) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmaceutical compositions comprising nebivolol |
| KR102882058B1 (ko) | 2018-03-28 | 2025-11-07 | 노바리크 게엠베하 | 티몰롤을 포함하는 약제학적 조성물 |
| JP2021522219A (ja) | 2018-04-27 | 2021-08-30 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| CN113710228A (zh) | 2019-02-13 | 2021-11-26 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的组合物和方法 |
| US12539302B2 (en) | 2019-08-07 | 2026-02-03 | Aneira Pharma, Inc. | Methods and compositions for the treatment of hair loss |
| EP4331683A3 (en) | 2019-08-07 | 2024-08-07 | Aneira Pharma, Inc. | Methods and compositions for the treatment of hair loss |
| US12419933B2 (en) | 2019-09-06 | 2025-09-23 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
| JP2022120120A (ja) * | 2022-06-13 | 2022-08-17 | 東亜薬品株式会社 | 眼科用水性組成物及びプロスタグランジンＦ２α誘導体の含量の低下を抑制する方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1300150T1 (de) * | 1988-09-06 | 2003-09-18 | Pharmacia Ab, Stockholm | Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| AU665287B2 (en) | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| AU7680096A (en) | 1995-12-22 | 1997-07-17 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
| JPH10259179A (ja) * | 1996-09-19 | 1998-09-29 | Santen Pharmaceut Co Ltd | 多置換アリールオキシ基を有するプロスタグランジン類およびその用途 |
| AR002194A1 (es) | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
| US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| JP4000505B2 (ja) * | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | 緑内障を治療するための併用剤 |
| SE0002211D0 (sv) | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
| US20020035148A1 (en) * | 2000-07-20 | 2002-03-21 | Ryuji Ueno | Treatment of ocular hypertension |
| JP3876355B2 (ja) * | 2000-09-13 | 2007-01-31 | 参天製薬株式会社 | 点眼液 |
| CA2422031C (en) * | 2000-09-13 | 2011-11-15 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solutions comprising difluoroprostaglandin f2 alpha |
| US20030018079A1 (en) * | 2000-11-13 | 2003-01-23 | Richardson Helene | Treatment |
| US8549114B2 (en) * | 2002-06-12 | 2013-10-01 | Bladelogic, Inc. | Method and system for model-based heterogeneous server configuration management |
| DK1532981T3 (da) | 2002-08-23 | 2008-01-28 | Santen Pharmaceutical Co Ltd | Stabile öjendråber, der indeholder latanoprost som den aktive bestanddel |
| CA2707067C (en) * | 2002-09-09 | 2013-07-16 | Santen Pharmaceutical Co., Ltd. | Clear ophthalmic solution comprising latanoprost as active ingredient |
-
2003
- 2003-05-06 US US10/429,677 patent/US7074827B2/en not_active Expired - Fee Related
- 2003-10-22 CA CA2502437A patent/CA2502437C/en not_active Expired - Fee Related
- 2003-10-22 AT AT03758746T patent/ATE480240T1/de active
- 2003-10-22 EP EP03758746A patent/EP1553953B1/en not_active Expired - Lifetime
- 2003-10-22 DK DK03758746.6T patent/DK1553953T3/da active
- 2003-10-22 EP EP10171708A patent/EP2253322A1/en not_active Withdrawn
- 2003-10-22 DE DE60334134T patent/DE60334134D1/de not_active Expired - Lifetime
- 2003-10-22 AU AU2003274734A patent/AU2003274734A1/en not_active Abandoned
- 2003-10-22 WO PCT/JP2003/013452 patent/WO2004037267A1/en not_active Ceased
- 2003-10-22 JP JP2005501572A patent/JP2006503913A/ja active Pending
-
2006
- 2006-05-23 US US11/438,290 patent/US8673973B2/en not_active Expired - Fee Related
-
2012
- 2012-05-31 JP JP2012125019A patent/JP2012162570A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1553953B1 (en) | 2010-09-08 |
| CA2502437C (en) | 2012-07-17 |
| US8673973B2 (en) | 2014-03-18 |
| AU2003274734A1 (en) | 2004-05-13 |
| US20060205725A1 (en) | 2006-09-14 |
| EP1553953A1 (en) | 2005-07-20 |
| JP2006503913A (ja) | 2006-02-02 |
| ATE480240T1 (de) | 2010-09-15 |
| US7074827B2 (en) | 2006-07-11 |
| CA2502437A1 (en) | 2004-05-06 |
| JP2012162570A (ja) | 2012-08-30 |
| EP2253322A1 (en) | 2010-11-24 |
| DE60334134D1 (de) | 2010-10-21 |
| WO2004037267A1 (en) | 2004-05-06 |
| US20040082660A1 (en) | 2004-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1553953T3 (da) | Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom | |
| DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
| ATE426413T1 (de) | Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen | |
| WO2006071548A3 (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases | |
| ECSP034815A (es) | "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas" | |
| DK1920764T4 (da) | Fluprostenolisopropylester til anvendelse ved behandling af glaukom og okulær hypertension | |
| BR0210241A (pt) | Piranoindazóis e seu uso no tratamento de glaucoma | |
| WO2003047513A3 (en) | Method for treating ocular hypertension | |
| WO2002009702A3 (en) | Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure | |
| ATE359794T1 (de) | 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes | |
| CY1108983T1 (el) | Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων | |
| EP1110554A4 (en) | MEDICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| NO20052751L (no) | Oftalmisk preparat for behandling av okulaer hypertensjon. | |
| ATE375141T1 (de) | Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer | |
| ATE453395T1 (de) | 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks | |
| BR0210238A (pt) | Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma | |
| ATE223200T1 (de) | Einen carboanhydrase-hemmer und xanthangummi enthaltendes augenarzneimittel | |
| WO2004043354A3 (en) | Ophthalmic compositions for treating ocular hypertension | |
| ATE216889T1 (de) | Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension | |
| DE69834638D1 (de) | Heilende zusammensetzung für intraokulare hypertension oder glaukom | |
| EP1515721A4 (en) | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA | |
| WO2002072105A3 (en) | Improved prostanoid therapies for the treatment of glaucoma | |
| ATE252387T1 (de) | Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen | |
| EP1482922A4 (en) | AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS | |
| NO20035043D0 (no) | Fremgangsmåte for behandling av okular hypertensjon og glaukom |